Neuroendocrine Carcinoma Market Report and Forecast (2025-2034)

The neuroendocrine carcinoma market size was valued at USD 2.44 Billion in 2024, driven by the rising prevalence of personalised medicine across the major markets. The market is expected to grow at a CAGR of 10.03% during the forecast period of 2025-2034, with the values likely to reach USD 6.35 Billion by 2034 .

Neuroendocrine Carcinoma: Introduction

Neuroendocrine carcinoma, also referred to as neuroendocrine tumour or neoplasm, initiates in specialized cells of the neuroendocrine system. These cells are present throughout the body and possess the traits of nerve cells as well as hormone producing endocrine cells. This tumour can affect any part of the body, including lungs, pancreas, and the GI (gastrointestinal) tract. Symptoms may vary depending upon the tumor location.

Neuroendocrine Carcinoma Market Analysis

As neuroendocrine carcinoma affects the hormone cells of the body, the repercussions range from skin rashes to diarrhoea to low or high blood pressure. In such cases, somatostatin analogues like octreotide and lanreotide are used. Chemotherapy, targeted therapy, peptide receptor radionuclide therapy are other non-pharmacological interventions used to treat the condition and aid in catering to the rising neuroendocrine carcinoma market demand.

With a specific focus on treating liver NET, radioembolization is being applied to slow down the tumour growth and shrink by directly offering radiation to the liver. This is done with the help of small radioactive particles, lodged inside the tumour to inhibit blood flow and emit radiation, damaging the cancer cells.

The neuroendocrine carcinoma market growth is driven by the increasing collaborations in prominent companies to expand their product portfolio and offer improved treatment alternatives to patients. In October 2023, Eli Lilly and Company acquired Point Biopharma Global to develop radioligand therapy for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The acquisition costed around USD 1.4 billion, which is an indicator that the market is experiencing hefty investments to foster innovation.

Neuroendocrine Carcinoma Market Segmentation

“Neuroendocrine Carcinoma Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Treatment Type

• Somatostatin Analogs (SSAs)
• Targeted Therapy
• Chemotherapy
• Others

Market Breakup by Indication

• Lungs
• Pancreas
• Gastrointestinal
• Others

Market Breakup by End User

• Hospitals
• Clinics
• Others

Market Breakup by Region

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan

Neuroendocrine Carcinoma Market Overview

The United States has dominated the neuroendocrine carcinoma market share, driven by the rising collaborations between research and academic institutions. In June 2023, Stanford University's Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) collaborated to develop treatments for cancerous neuroendocrine tumors. With a robust healthcare infrastructure, the region is expected to lead the market in the forecast period as well.

Europe is another major market with numerous well-equipped healthcare and research infrastructure to foster new therapies for neuroendocrine carcinoma treatment. Major collaborations amongst healthcare companies are also contributing to the market value.

With continuously improving medical ecosystem, the Asia Pacific region, particularly Japan, is anticipated to experience maximum neuroendocrine carcinoma market growth. To leverage the academic talent and other resources, countries with emerging economies like India, and South Korea are also witnessing an influx of foreign capital. Such investments may boost the market growth significantly in the forecast period.

Neuroendocrine Carcinoma Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb
• Eli Lilly & Company
• F. Hoffmann-La Roche Ltd.
• Ipsen
• Baxter
• Novartis AG
• Pfizer Inc.
• Lantheus Holdings, Inc.
• Tarveda Therapeutics
• AVEO Pharmaceuticals, Inc.
• Advanced Accelerator Applications
• BioSynthema Inc.
• Merck Sharp & Dohme Corp.
• Bionano Genomics

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

This product will be delivered within 3-5 business days.